Iterum TherapeuticsITRMF +18.86% Days Payable is 4,028.69 as of Sep. 2025, which is 7% above its 10-year median of 3,769.99. The stock has 4 warning signs investors should review. Among 708 Biotechnology companies, Iterum Therapeutics ranks better than 67.09% on this metric.
The historical rank and industry rank for Iterum Therapeutics's Days Payable or its related term are showing as below:
ITRMF'
s Days Payable Range Over the Past 10 Years
Min: 248.02 Med: 3769.99 Max: 3769.99
Current: 248.02
During the past 9 years, Iterum Therapeutics's highest Days Payable was 3769.99. The lowest was 248.02. And the median was 3769.99.
ITRMF's Days Payable is ranked better than 67.09% of 708
companies
in the Biotechnology industry
Industry Median: 113.56
vs ITRMF: 248.02
Iterum Therapeutics's Days Payable
increased
from Sep. 2024 (0.00) to Sep. 2025 (4,028.69).
It may suggest that Iterum Therapeuticsdelayed paying its suppliers.
Iterum Therapeutics Days Payable Related Terms
Iterum Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Iterum Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ITRMF vs ENSC, PPCB, REVB: Days Payable Comparison
For the Biotechnology subindustry, Iterum Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Iterum Therapeutics's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics (ITRMF) has a Days Payable of 4,028.69 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Iterum Therapeutics and its competitors. This is near median its historical median of 3,769.99. Over the past decade, Iterum Therapeutics' Days Payable has ranged from 248.02 to 3,769.99. According to the industry distribution chart, Iterum Therapeutics ranks #233 out of 708 companies in the Biotechnology industry, placing it in the top 32.9%.
Is Iterum Therapeutics' Days Payable too high?
Iterum Therapeutics' current Days Payable of 4,028.69 is near median its 10-year median of 3,769.99. Over the past 10 years, this metric has ranged from a low of 248.02 to a high of 3,769.99. The Biotechnology industry median Days Payable is 113.56. Iterum Therapeutics' value of 4,028.69 is 3447.6% above this industry median. Based on the distribution chart, Iterum Therapeutics ranks #233 out of 708 companies in the Biotechnology industry, which is above the industry midpoint.
How does Iterum Therapeutics' Days Payable compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #233 out of 708 companies for Days Payable. This puts Iterum Therapeutics in the upper half of its industry. The industry median Days Payable is 113.56. Iterum Therapeutics' value of 4,028.69 is 3447.6% above this benchmark. Historically, Iterum Therapeutics' own Days Payable has ranged from 248.02 to 3,769.99 over the past decade. While the company's 10-year median is 3,769.99 vs. the industry median of 113.56, Iterum Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iterum Therapeutics's current Days Payable of 4,028.69 is 3447.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Iterum Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iterum Therapeutics's current Days Payable is 4,028.69, which is near median its own 10-year median of 3,769.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Days Payable of 4,028.69. The current Days Payable is 4,028.69, which is near median its 10-year median of 3,769.99 and 3447.6% above the Biotechnology industry median of 113.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Days Payable is 4,028.69 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITRMF has been successfully added to your 